Certain factors may increase the likelihood of experiencing bloating on GLP-1 therapy, including: Pre-existing gastrointestinal conditions such as irritable bowel syndrome (IBS), functional dyspepsia, or small intestinal bacterial overgrowth (SIBO) Rapid dose escalation without adequate titration periods Dietary factors , particularly high intake of fermentable carbohydrates (FODMAPs), fatty foods, or carbonated beverages Concurrent medications that affect gastrointestinal motility Patients should be aware that GLP-1 receptor agonists have been associated with more serious gastrointestinal adverse effects, including pancreatitis (inflammation of the pancreas) and gallbladder disease
et al., SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
alone, over 42,000 deaths [archived link] could be prevented each year if everyone who might benefit from taking a GLP-1 RA had access
Preference for oral medication : Ideal for those who prefer pills over injections
Cape Fear Physical Medicine and Rehab emphasizes individualized care and a holistic approach to health
On the other hand, in the retrospective cohort study using TriNetX Analytics Network electronic health records, semaglutide significantly lowered the risk of both new (HR, 0.27
